|
|
|||||||||
CA: A Cancer Journal for Clinicians, Vol 42, Issue 6 327-349, Copyright © 1992 by American Cancer Society
C. D. Runowicz
Ovarian cancer is the leading cause of death from gynecologic malignancies.
This article reviews the newer chemotherapeutic agents and treatment
strategies available to the practicing clinician. Also discussed are the
benefits and shortfalls of the various options for screening, such as
ultrasound and tumor markers, as well as the data supporting oral
contraceptives and the controversy surrounding prophylactic oophorectomy.
ARTICLES
Advances in the screening and treatment of ovarian cancer
Department of Obstetrics and Gynecology, Albert Einstein College of Medicine, Bronx, New York.
This article has been cited by other articles:
![]() |
G. S. Hagopian, G. B. Mills, A. R. Khokhar, R. C. Bast Jr., and Z. H. Siddik Expression of p53 in Cisplatin-resistant Ovarian Cancer Cell Lines: Modulation with the Novel Platinum Analogue (1R, 2R-Diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV) Clin. Cancer Res., March 1, 1999; 5(3): 655 - 663. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | COVER ARCHIVE | SEARCH | TABLE OF CONTENTS |